Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit- Hagens Berman
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit- Hagens Berman IOVA Investors with Losses Encouraged to Contact Hagens Berman GlobeNewswire June 04, 2025 SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its […]